TriangleNCT00392327 · OUTCOME
Percent Probability of Event-free Survival (EFS) for Patients With Supratentorial Primitive Neuroectodermal Tumor (SPNET)
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- NUMBER
- Unit
- Percent Probability
- Interval / dispersion
- 95% Confidence Interval
- Time frame
- Up to 5 years
What was measured
The Kaplan-Meier method will be used to estimate 5-year EFS, defined as the time from study enrollment to disease progression or recurrence, second malignant neoplasm, or death from any cause, or to date of last contact. Estimates are reported with 95% confidence intervals.
Analysis population: Eligible SPNET patients are included.
Groups in this outcome
Regimen A (SPNET Patients)
SPNET patients who received regimen A (no carboplatin / no isotretinoin)
Regimen B (SPNET Patients)
SPNET patients who received regimen B (carboplatin / no isotretinoin)
Regimen C (SPNET Patients)
SPNET patients who received regimen C (no carboplatin / isotretinoin)
Regimen D (SPNET Patients)
SPNET patients who received regimen D (carboplatin / isotretinoin)
| Group | Source count |
|---|---|
| Regimen A (SPNET Patients) | 23 |
| Regimen B (SPNET Patients) | 19 |
| Regimen C (SPNET Patients) | 21 |
| Regimen D (SPNET Patients) | 22 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Regimen A (SPNET Patients) | 52.2 | Not reported | 32.6 | 71.8 | Not reported |
| Regimen B (SPNET Patients) | 52.6 | Not reported | 31.2 | 74.0 | Not reported |
| Regimen C (SPNET Patients) | 19 | Not reported | 3.9 | 34.1 | Not reported |
| Regimen D (SPNET Patients) | 63 | Not reported | 43.0 | 83.0 | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- lower Limit
- 32.6
- upper Limit
- 71.8
- value
- 52.2
- group Id
- OG001
- lower Limit
- 31.2
- upper Limit
- 74.0
- value
- 52.6
- group Id
- OG002
- lower Limit
- 3.9
- upper Limit
- 34.1
- value
- 19
- group Id
- OG003
- lower Limit
- 43.0
- upper Limit
- 83.0
- value
- 63
- denoms
- counts
- group Id
- OG000
- value
- 23
- group Id
- OG001
- value
- 19
- group Id
- OG002
- value
- 21
- group Id
- OG003
- value
- 22
- units
- Participants
- description
- The Kaplan-Meier method will be used to estimate 5-year EFS, defined as the time from study enrollment to disease progression or recurrence, second malignant neoplasm, or death from any cause, or to date of last contact. Estimates are reported with 95% confidence intervals.
- dispersion Type
- 95% Confidence Interval
- groups
- description
- SPNET patients who received regimen A (no carboplatin / no isotretinoin)
- id
- OG000
- title
- Regimen A (SPNET Patients)
- description
- SPNET patients who received regimen B (carboplatin / no isotretinoin)
- id
- OG001
- title
- Regimen B (SPNET Patients)
- description
- SPNET patients who received regimen C (no carboplatin / isotretinoin)
- id
- OG002
- title
- Regimen C (SPNET Patients)
- description
- SPNET patients who received regimen D (carboplatin / isotretinoin)
- id
- OG003
- title
- Regimen D (SPNET Patients)
- param Type
- NUMBER
- population Description
- Eligible SPNET patients are included.
- reporting Status
- POSTED
- time Frame
- Up to 5 years
- title
- Percent Probability of Event-free Survival (EFS) for Patients With Supratentorial Primitive Neuroectodermal Tumor (SPNET)
- type
- PRIMARY
- unit Of Measure
- Percent Probability
Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0
Preserved source evidence · Not medical advice